Clinical Trials Logo

Viral Hepatitis C clinical trials

View clinical trials related to Viral Hepatitis C.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04047680 Completed - Hepatitis C Clinical Trials

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Start date: February 2015
Phase:
Study type: Observational

Data regarding the nephrotoxicity of sofosbuvir (SOF) remain controversial. The investigators compared the changes of estimated glomerular filtration rate (eGFR) in patients with chronic hepatitis C virus (HCV) infection receiving SOF-based or SOF-free direct acting antivirals (DAAs).

NCT ID: NCT03566966 Completed - Viral Hepatitis C Clinical Trials

Autoantibodies and Direct-acting Antivirals

BIOEPA
Start date: July 1, 2015
Phase:
Study type: Observational [Patient Registry]

The investigators assessed non-organ-specific antibodies before and 24 weeks after the end of therapy with direct-acting antivirals, in order to better clarify the clinical relevance of these antibodies in terms of treatment response and prognostic value. To achieve this goal patients with hepatitis C virus related advanced liver disease, with detectable circulating autoantibodies on at least two determinations before treatment, were enrolled.

NCT ID: NCT03537196 Completed - Hepatitis C Clinical Trials

DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)

DRIVE-C
Start date: November 13, 2018
Phase: Phase 4
Study type: Interventional

The study aims to assess the effectiveness of a model of hepatitis C screening and integrated care, targeting people who inject drugs (PWIDs) in Hai Phong, Vietnam. In a wider perspective, this model linked to mass screening through repeated Respondent Driven Sampling (RDS) surveys, to simplified treatment protocol, and to large community-based support to improve referral to care, retention in care, adherence to treatment and prevention of reinfection, may have the potential to eliminate HCV among PWIDs in this city.

NCT ID: NCT02125500 Completed - HIV Clinical Trials

Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection

Start date: August 2014
Phase: Phase 2
Study type: Interventional

Aim of the study is to assess the efficacy and safety of 24 weeks of oral Sofosbuvir/Ledipasvir fixed-dose combination (FDC) in subjects with HCV genotype 1 infection and HIV co-infection, who have previously failed a NS3/4A protease inhibitor plus Pegylated interferon /ribavirin regimen or stopped prematurely their treatment for intolerance.